Claims
- 1. A composition comprising a pharmaceutically acceptable carrier and a compound of the formula (1):
- 2. The composition of claim 1, wherein compound (3) is a compound of the formula (2):
- 3. The composition of claim 1, wherein R1 and R2 are hydrogen.
- 4. The composition of claim 1, wherein R3 is halogen.
- 5. The composition of claim 4, wherein R3 is chlorine or fluorine.
- 6. The composition of claim 1, wherein R3 is hydrogen.
- 7. A composition comprising a pharmaceutically acceptable carrier and a compound (1):
- 8. A method of inhibiting the binding of a chemokine, which is MIP-1α or RANTES, to a CCR1 receptor, comprising contacting the composition of claim 1 or 2 with a cell that expresses the CCR1 receptor for a time sufficient to inhibit the binding of the chemokine to the CCR1 receptor.
- 9. A method of treating an inflammatory disease, comprising administering a therapeutically effective amount of the composition of claim 1 or 2 to a patient in need thereof for a time sufficient to treat the inflammatory disease.
FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0001] Defense Advanced Research Projects Agency (DARPA) Grant No. N65236-99-1-5420.